Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $115-125 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
